Pertuzumab, a humanised monoclonal antibody which inhibits dimerisation of HER2 and HER3 receptors, is used in conjunction with trastuzumab and chemotherapy for HER2-positive breast cancer in both locally advanced and metastatic settings [95,96]. This evidence concerns the gene ERBB2 and breast carcinoma.